Pharsight

Drugs that contain Tipiracil Hydrochloride; Trifluridine

1. Lonsurf patents expiration

LONSURF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10457666 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(10 years from now)

US9527833 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46284 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Sep, 2029

(5 years from now)

US9943537 TAIHO ONCOLOGY Antitumor agent and antitumor effect enhancer
Sep, 2034

(10 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 22, 2026

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if ...

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's drug patent expiration?
More Information on Dosage

LONSURF family patents

Family Patents